Investigational Study of Accommodation Triggering and Control to Allow for the Performance of Refraction Measurements
An Investigational Study of Accommodation Triggering and Control to Allow for the Performance of Refraction Measurements
1 other identifier
interventional
38
1 country
1
Brief Summary
An investigational study in the control of the user's accommodative state via visual stimuli.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2019
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 9, 2019
CompletedFirst Posted
Study publicly available on registry
May 21, 2019
CompletedStudy Start
First participant enrolled
September 3, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 18, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 18, 2020
CompletedMarch 24, 2021
January 1, 2020
1.3 years
May 9, 2019
March 23, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Accommodative Response
Measurement of accommodative response by measuring visual refraction while the subject is viewing various visual stimuli.
Through study completion, an average of 5 months
Study Arms (1)
Visual Stimuli
EXPERIMENTALParticipants will be presented various visual stimuli in which accommodative response is measured.
Interventions
Subjects will be presented various visual stimuli and may be asked to perform tasks. Their accommodative response will be measured.
Eligibility Criteria
You may qualify if:
- Male or Female
- Age 18 through 30 years at the time of consent
- Binocular vision
- Willing and able to give informed consent and follow all study procedures and requirements
- Fluent in English
You may not qualify if:
- Spherical correction \> +4D or \< -5D, astigmatism \< -2.5D.
- Using anticholinergic medications (including first-generation antihistamines) or other medications known to affect visual acuity within the greater of 3 days or 5 half-lives prior to enrolling in this study
- Using an investigational drug or approved therapy for investigational use within the greater of 3 days or 5 half-lives prior to enrolling in this study
- Has initiated any new medication in the past 2 weeks that, in the best medical judgment of the investigator, would impact their participation in the study or ability to use EyeQue devices
- Reported or observed eye disease or pathology, including but not limited to:
- Glaucoma
- Cataracts
- Macular degeneration
- Eye infection
- Keratoconus
- Diabetic neuropathy/retinopathy
- Cytomegalovirus retinitis
- Color blindness (any color deficiency)
- Diabetic macular edema
- Amblyopia
- +8 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- EyeQue Corp.lead
Study Sites (1)
EyeQue
Newark, California, 94560, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Noam Sapiens
EyeQue Corp.
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 9, 2019
First Posted
May 21, 2019
Study Start
September 3, 2019
Primary Completion
December 18, 2020
Study Completion
December 18, 2020
Last Updated
March 24, 2021
Record last verified: 2020-01